Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Phase 3

Active, not recruiting

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Capecitabine

First Posted Date: 2023-05-03

Last Posted Date: 2024-08-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 654

Registration Number: NCT05840211

Locations: 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇲🇽
Centro de Atención e Investigación Clínica en Oncología, Yucatán, Mexico
🇵🇱
Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, Poland

and more 283 locations

Adaptive Radiation in Anal Cancer

Not Applicable

Recruiting

Conditions: Anal Squamous Cell Carcinoma

Interventions: Radiation: Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
Drug: Mitomycin-C
Drug: 5-Fluorouracil
Drug: Capecitabine

First Posted Date: 2023-05-01

Last Posted Date: 2024-07-11

Lead Sponsor: Columbia University

Target Recruit Count: 20

Registration Number: NCT05838391

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2

Active, not recruiting

Conditions: Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Echocardiography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Lymphadenectomy
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure

First Posted Date: 2023-05-01

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT05836584

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Dublin, Dublin, California, United States

and more 133 locations

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Capecitabine

First Posted Date: 2023-04-27

Last Posted Date: 2023-04-27

Lead Sponsor: Consorzio Oncotech

Target Recruit Count: 122

Registration Number: NCT05833919

Locations: 🇮🇹
Università Campus Biomedico, Roma, Italy
🇮🇹
Istituto Nazionale dei Tumori - Fondazione G. Pascale, Napoli, Italy
🇮🇹
ASUFC P.O. "Santa Maria della Misericordia", Udine, Italy

and more 22 locations

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Phase 2

Recruiting

Conditions: Adenocarcinoma of the Pancreas

Interventions: Drug: Gemcitabine 1000 mg
Drug: Valproic acid
Drug: Nab paclitaxel
Drug: Simvastatin 20mg
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2023-04-20

Last Posted Date: 2024-06-18

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 240

Registration Number: NCT05821556

Locations: 🇮🇹
Università vita e Salute, IRCCS San Raffaele, Milano, Italy
🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
🇮🇹
University of Verona Hospital Trust, Verona, Italy

and more 2 locations

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer
MSS

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05815303

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1

Recruiting

Conditions: Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-04-07

Last Posted Date: 2024-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05803382

Locations: 🇺🇸
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
🇺🇸
Siteman Cancer Center-South County, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States

and more 16 locations